false 0001651431 0001651431 2021-11-12 2021-11-12





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2021




(Exact name of registrant as specified in its charter)




Delaware   001-39425   36-4813934

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


Checkmate Pharmaceuticals, Inc.
245 Main Street, 2nd Floor
Cambridge, MA 02142
(Address of principal executive offices, including zip code)

(617) 682-3625

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   CMPI   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 2.02

Results of Operations and Financial Condition

On November 12, 2021, Checkmate Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits


99.1    Press release issued by Checkmate Pharmaceuticals, Inc. on November 12, 2021, furnished herewith.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Checkmate Pharmaceuticals, Inc.
Date: November 12, 2021     By:  

/s/ Robert Dolski

      Robert Dolski
      Chief Financial Officer
EX-99.1 2 d254416dex991.htm EX-99.1 EX-99.1


Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

Alan Fuhrman appointed interim President and CEO

Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer ongoing

Clinical data readouts anticipated in 2022

CAMBRIDGE, Mass., November 12, 2021Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced third quarter 2021 financial results and provided a business update.

“We are excited about the future of vidutolimod as a potential novel treatment for multiple tumor types, including melanoma and head and neck cancer. We continue to advance our clinical trials towards potential data readouts in 2022,” said Alan Fuhrman, interim President and Chief Executive Officer of Checkmate.

Recent Business Updates



During The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, Dr. John Kirkwood from the University of Pittsburgh Medical Center presented a poster on the final clinical data from the Phase 1b study of vidutolimod in combination with pembrolizumab or as a monotherapy in patients with anti-PD-1 refractory melanoma.



Vidutolimod in combination with pembrolizumab led to an ORR of 23.5% by RECIST v1.1, a complete response rate of 7.1%, and a median duration of response of 25.2 months.



Vidutolimod monotherapy resulted in a 20.0% ORR by RECIST v1.1 and a median duration of response of 5.6 months.



The most frequent treatment-related adverse events were consistent with flu-like symptoms and injection site reactions and were most commonly Grade 1 or 2.



We appointed Alan Fuhrman, an experienced biotech executive and Checkmate board member, as interim President and CEO.



Ongoing patient recruitment activities and enrollment across our clinical trials evaluating vidutolimod, including:



A Phase 2 trial of vidutolimod in combination with nivolumab in anti-PD-1 refractory advanced melanoma, supported by a clinical collaboration with Bristol Myers Squibb.



A randomized Phase 2/3 trial of vidutolimod in combination with nivolumab vs. nivolumab monotherapy in first-line metastatic or unresectable melanoma, also supported by the clinical collaboration with Bristol Myers Squibb.



A Phase 2 trial of vidutolimod in combination with pembrolizumab in recurrent or metastatic squamous cell head and neck cancer.


Start-up activities underway for the planned expansion of the development program for vidutolimod in combination with cemiplimab in cutaneous squamous cell carcinoma and Merkel cell carcinoma, supported by a clinical collaboration with Regeneron.

Third Quarter 2021 Financial Results



Research and development expenses (R&D): R&D expenses for the three months ending September 30, 2021, were $11.4 million, compared to $6.7 million for the same period in the prior year. This increase reflects higher third-party CRO and manufacturing costs directly related to the vidutolimod clinical trials, in addition to higher personnel and operating expense for the planning and execution of the clinical trials.



General and administration expenses (G&A): G&A expenses for the three months ending September 30, 2021, were $3.6 million, compared to $3.2 million for the same period in the prior year. This increase was primarily attributable to increases in personnel and operating expense incurred in connection with Checkmate operating as a publicly traded company.



Cash, cash equivalents and investments: Cash, cash equivalents and available-for-sale investments were $80.8 million as of September 30, 2021.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

Availability of Other Information About Checkmate Pharmaceuticals

Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward Looking Statements

Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. These statements include those regarding vidutolimod (formerly CMP-001), including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of clinical data and timing thereof; expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for vidutolimod and the benefits and related implications of current and future partnerships and/or collaborations; and expectations regarding the Company’s use of capital, expenses and other financial results. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the period ending September 30, 2021 and in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) which is available on the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the SEC. All information in this press release is as of the date of the release, and we undertake no duty to update this information unless required by law.

Investor Contact

Rob Dolski

Chief Financial Officer


Media Contact

Karen Sharma







(In thousands, except per share amounts)


     Three Months Ended
September 30,
    Nine Months Ended
September 30,
     2021     2020     2021     2020  

Operating expenses:


Research and development

   $ 11,375     $ 6,673     $ 36,618     $ 19,462  

General and administrative

     3,605       3,160       11,498       6,465  













Total operating expenses

     14,980       9,833       48,116       25,927  













Loss from operations

     (14,980     (9,833     (48,116     (25,927













Other income (expense), net:


Interest income

     14       4       87       32  

Loss on sale of available-for-sale investments

     —         —         (35     —    

Change in fair value of convertible loan notes

     —         —         —         (83













Total other income (expense), net

     14       4       52       (51













Net loss

   $ (14,966   $ (9,829   $ (48,064   $ (25,978













Weighted-average common shares outstanding – basic and diluted

     21,626       13,580       21,611       5,519  













Net loss per share attributable to common stockholders – basic and diluted

   $ (0.69   $ (0.84   $ (2.22   $ (5.79
















(In thousands)


     September 30,
     December 31,

Cash, cash equivalents and investments

   $ 80,844      $ 125,859  

Other assets

     8,495        7,215  







Total assets

   $ 89,339      $ 133,074  







Total liabilities

     7,812        7,875  

Total stockholders’ equity

     81,527        125,199  







Total liabilities and stockholders’ equity

   $ 89,339      $ 133,074  






EX-101.SCH 3 cmpi-20211112.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cmpi-20211112_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 cmpi-20211112_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 d254416d8k_htm.xml IDEA: XBRL DOCUMENT 0001651431 2021-11-12 2021-11-12 false 0001651431 8-K 2021-11-12 CHECKMATE PHARMACEUTICALS, INC. DE 001-39425 36-4813934 Checkmate Pharmaceuticals, Inc. 245 Main Street 2nd Floor Cambridge MA 02142 (617) 682-3625 false false false false Common Stock, $0.0001 par value per share CMPI NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 12, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001651431
Document Type 8-K
Document Period End Date Nov. 12, 2021
Entity Incorporation State Country Code DE
Entity File Number 001-39425
Entity Tax Identification Number 36-4813934
Entity Address, Address Line One Checkmate Pharmaceuticals, Inc.
Entity Address, Address Line Two 245 Main Street
Entity Address, Address Line Three 2nd Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 682-3625
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol CMPI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d254416d8k.htm cmpi-20211112.xsd cmpi-20211112_lab.xml cmpi-20211112_pre.xml d254416dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d254416d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d254416d8k.htm" ] }, "labelLink": { "local": [ "cmpi-20211112_lab.xml" ] }, "presentationLink": { "local": [ "cmpi-20211112_pre.xml" ] }, "schema": { "local": [ "cmpi-20211112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cmpi", "nsuri": "http://www.checkmatepharma.com/20211112", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d254416d8k.htm", "contextRef": "duration_2021-11-12_to_2021-11-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d254416d8k.htm", "contextRef": "duration_2021-11-12_to_2021-11-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.checkmatepharma.com//20211112/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-21-327299-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-327299-xbrl.zip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end